Talazoparib plus chest radiation after extensive small-cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This Phase 1 trial tests whether the medicine talazopib, given along with chest radiation, can better control extensive-stage small-cell lung cancer after initial chemotherapy. It is for people whose cancer has not worsened after finishing standard chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed small-cell lung cancer (SCLC) diagnosed by a pathologist at the study site
- Your SCLC is “extensive stage,” and you finished 4–6 cycles of standard chemotherapy
- Your cancer did not get worse after chemotherapy (it was stable or better)
- You are generally well enough for treatment (ECOG 0 to 2, or KPS at least 50)
- Your blood counts and organs (like liver/kidney) are strong enough for study drugs
- You can take the study medicine by mouth and do not have bowel problems that would block absorption
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of low-dose radiation, an immunotherapy drug (sugemalimab), chemotherapy, and a targeted drug (olaparib) as a first treatment for people with extensive-stage small cell lung cancer that has a specific marker called SLFN-11. The goal is to see if this combination is safe and works better than standard treatment.
This Phase 1 study tests whether the cancer drug talazoparib, combined with radiation, can better control recurrent gynecologic cancers in the pelvis/abdomen. It focuses on patients whose cancer has come back locally enough that radiation can be given, while other disease is not rapidly worsening.
This trial tests a drug called talazoparib (a PARP inhibitor) for advanced breast cancer that has a specific DNA repair defect (HRD) or a BRCA mutation. The goal is to see if the drug works better when the patient's tumor is tested for this defect just before treatment.
This Phase 2 study tests whether combining pembrolizumab and olaparib can improve outcomes in people with extensive-stage small cell lung cancer. It mainly aims to shrink tumors and help control the cancer for longer.
This Phase 2 trial tests talazoparib, a targeted cancer medicine, in people with metastatic breast cancer that has a harmful BRCA1 or BRCA2 mutation found in tumor DNA circulating in the blood. If you qualify, the goal is to see how well this treatment works when the mutation is detected this specific way.
This trial studies talazoparib (a targeted pill) in people with advanced breast cancer whose tumors have problems repairing certain DNA damage. If your tumor has these specific “DNA repair” defects, the medicine may work better and stop the cancer from growing.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.